Drug Trial Radar · NCT04987203
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
343
Actual
Start
Sep 9, 2021
Primary completion
Jan 20, 2026
Study completion Jan 20, 2026
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel; Bristol-Myers Squibb
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).
Conditions
- Renal Cell Carcinoma
Interventions
TivozanibDrug
Tivozanib will be administered orally.
NivolumabDrug
Nivolumab will be administered via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: Until progressive disease [PD] (Approximately 30 months)
Locations
139 sites in 16 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Chao Family Comprehensive Cancer Center, UC Irvine
Irvine, California
University of California San Diego
La Jolla, California
Leland Stanford Junior University
Redwood City, California
Kaiser Permanente Riverside Medical Center
Riverside, California
US Oncology - Rocky Mountain Cancer Centers - Midtown
Denver, Colorado
Florida Cancer Specialists & Res Inst
Fort Myers, Florida
Florida Cancer Specialists & Research Institute (FCS) - Tampa Cancer Center Location
St. Petersburg, Florida
The University of Kansas Cancer Center
Westwood, Kansas
University of Kentucky UK Markey Cancer Center
Lexington, Kentucky
Tulane Cancer Center Clinic - Oncology
New Orleans, Louisiana
University of Maryland Medical Center-Greenebaum Cancer Ctr
Baltimore, Maryland
John Hopkins Medicine - Hematology/oncology
Baltimore, Maryland
Maryland Oncology Hematology
Clinton, Maryland
Dana-Farber Cancer Institute - Medicine
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
St. Vincent Frontier Cancer Center
Billings, Montana
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska
Memorial Sloan Kettering Cancer Center - Monmouth - Oncology
Middletown, New Jersey
University of New Mexico - Comprehensive Cancer Center
Albuquerque, New Mexico
Roswell - Roswell Park Cancer Institute - Medical Oncology
Buffalo, New York
Memorial Sloan Kettering Cancer Center - Westchester
East White Plains, New York
Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital
New York, New York
Memorial Sloan Kettering Cancer Center - Nassau
Uniondale, New York
Cleveland Clinic
Cleveland, Ohio
Lehigh Valley Physician Group
Allentown, Pennsylvania
Allegheny General Hospital (AGH)
Pittsburgh, Pennsylvania
UH Cleveland Medical Center
Columbia, South Carolina
Chattanooga Oncology and Hematology Associates
Chattanooga, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Texas Oncology - Central Austin Cancer Center
Austin, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
US Oncology Texas Oncology (CCC of South Texas) - San Antonio Medical Center
San Antonio, Texas
University Of Washington - Medical Center
Seattle, Washington
Northwest Medical Specialties PLLC
Tacoma, Washington
Centro Oncológico Korben
Buenos Aires, Ciudad Autónoma de Buenos Aire, Argentina
Clínica Viedma
Viedma, Río Negro Province, Argentina
Centro Oncologico de Rosario
Rosario, Santa Fe Province, Argentina
Centro para la Atención Integral del paciente Oncológico
San Miguel de Tucumán, Tucumán Province, Argentina
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.